



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

DIVISION OF
CORPORATION FINANCE

September 23, 2022

Vlad Coric, M.D.
Chief Executive Officer
Biohaven Pharmaceutical Holding Co Ltd.
215 Church Street
New Haven, CT 06510

Re: Biohaven Pharmaceutical Holding Co Ltd.
Preliminary Proxy Statement on Schedule 14A
Filed July 1, 2022
File No. 001-38080

Dear Dr. Coric:

We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Sincerely,

Division of Corporation Finance
Office of Life Sciences

cc: Robert Downes, Esq.